We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Strength Seen in Orchestra BioMed Holdings, Inc. (OBIO): Can Its 5.2% Jump Turn into More Strength?
Read MoreHide Full Article
Orchestra BioMed Holdings, Inc. (OBIO - Free Report) shares soared 5.2% in the last trading session to close at $6.08. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 6.5% gain over the past four weeks.
Orchestra BioMed’s share price gain was driven by investor optimism around its investigational atrioventricular interval modulation therapy, which was featured in two sessions at HRX Live 2026 for its potential to treat uncontrolled hypertension in patients indicated for a cardiac pacemaker. The stock also benefited from a $6.1 million milestone payment following Haemonetics’ acquisition of Vivasure, strengthening OBIO’s cash position. The payment completes the proceeds expected in 2026, while the company remains eligible for up to $10 million in additional earnout payments tied to future milestones.
This company is expected to post quarterly loss of $0.40 per share in its upcoming report, which represents no change from the year-ago quarter. Revenues are expected to be $0.11 million, down 87.2% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Orchestra BioMed Holdings, Inc., the consensus EPS estimate for the quarter has been revised 2.4% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on OBIO going forward to see if this recent jump can turn into more strength down the road.
Orchestra BioMed Holdings, Inc. is a member of the Zacks Medical - Biomedical and Genetics industry. One other stock in the same industry, Arcutis Biotherapeutics, Inc. (ARQT - Free Report) , finished the last trading session 4.1% lower at $25.38. ARQT has returned 4.4% over the past month.
Arcutis Biotherapeutics' consensus EPS estimate for the upcoming report has remained unchanged over the past month at $0.17. Compared to the company's year-ago EPS, this represents a change of +183.3%. Arcutis Biotherapeutics currently boasts a Zacks Rank of #2 (Buy).
View the Zacks #1 Rank List
Image: Bigstock
Strength Seen in Orchestra BioMed Holdings, Inc. (OBIO): Can Its 5.2% Jump Turn into More Strength?
Orchestra BioMed Holdings, Inc. (OBIO - Free Report) shares soared 5.2% in the last trading session to close at $6.08. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 6.5% gain over the past four weeks.
Orchestra BioMed’s share price gain was driven by investor optimism around its investigational atrioventricular interval modulation therapy, which was featured in two sessions at HRX Live 2026 for its potential to treat uncontrolled hypertension in patients indicated for a cardiac pacemaker. The stock also benefited from a $6.1 million milestone payment following Haemonetics’ acquisition of Vivasure, strengthening OBIO’s cash position. The payment completes the proceeds expected in 2026, while the company remains eligible for up to $10 million in additional earnout payments tied to future milestones.
This company is expected to post quarterly loss of $0.40 per share in its upcoming report, which represents no change from the year-ago quarter. Revenues are expected to be $0.11 million, down 87.2% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Orchestra BioMed Holdings, Inc., the consensus EPS estimate for the quarter has been revised 2.4% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on OBIO going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Orchestra BioMed Holdings, Inc. is a member of the Zacks Medical - Biomedical and Genetics industry. One other stock in the same industry, Arcutis Biotherapeutics, Inc. (ARQT - Free Report) , finished the last trading session 4.1% lower at $25.38. ARQT has returned 4.4% over the past month.
Arcutis Biotherapeutics' consensus EPS estimate for the upcoming report has remained unchanged over the past month at $0.17. Compared to the company's year-ago EPS, this represents a change of +183.3%. Arcutis Biotherapeutics currently boasts a Zacks Rank of #2 (Buy).